Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2013

Open Access 01-12-2013 | Research article

Snail expression and outcome in T1 high-grade and T2 bladder cancer: a retrospective immunohistochemical analysis

Authors: Shunichiro Nomura, Yasutomo Suzuki, Ryo Takahashi, Mika Terasaki, Ryoji Kimata, Tsutomu Hamasaki, Go Kimura, Akira Shimizu, Yukihiro Kondo

Published in: BMC Urology | Issue 1/2013

Login to get access

Abstract

Background

Neoadjuvant chemotherapy has been shown to have benefit in T1 high-grade or T2 bladder cancer. However, neoadjuvant chemotherapy fails in some patients. Careful patient selection for neoadjuvant chemotherapy is therefore needed. Several reports show that Snail is associated with resistance to chemotherapy. We hypothesized that Snail expression could predict survival in T1 high-grade and T2 bladder cancer patients treated with neoadjuvant chemotherapy.

Methods

The participants were 44 patients with T1 high-grade and T2 bladder cancer receiving neoadjuvant chemotherapy. Immunohistochemical analysis was used to determine Snail expression in specimens of bladder cancer obtained by transurethral resection before neoadjuvant chemotherapy. The relationships between Snail expression and patients’ outcomes were analyzed.

Results

Snail expression was positive in 15 of the 44 patients (34.1%) and negative in 29 (65.9%). Disease-free survival was significantly shorter for the Snail-positive group than for the Snail-negative group (p = 0.014). In addition, disease-specific survival was also significantly shorter for the Snail-positive group than for the Snail-negative group (p = 0.039). In multivariate analysis, Snail expression level was identified as an independent prognostic factor for disease-specific survival (p = 0.020).

Conclusions

The results indicate that Snail expression may predict poor outcome in T1 high-grade and T2 bladder cancer patients treated with neoadjuvant chemotherapy.
Appendix
Available only for authorised users
Literature
1.
Ploeg M, Aben KK, Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 2009, 27 (3): 289-293. 10.1007/s00345-009-0383-3.CrossRefPubMedPubMedCentral
2.
Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, Pagano F: Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol. 1999, 161 (5): 1494-1497. 10.1016/S0022-5347(05)68936-7.CrossRefPubMed
3.
Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, Reuter V: Cystectomy for bladder cancer: a contemporary series. J Urol. 2001, 165 (4): 1111-1116. 10.1016/S0022-5347(05)66440-3.CrossRefPubMed
4.
Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A: Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol. 1997, 158 (2): 393-399. 10.1016/S0022-5347(01)64487-2.CrossRefPubMed
5.
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Urol. 2001, 19 (3): 666-675.
6.
Stein JP, Skinner DG: Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006, 24 (3): 296-304. 10.1007/s00345-006-0061-7.CrossRefPubMed
7.
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005, 48 (2): 202-205. 10.1016/j.eururo.2005.04.006. discussion 205–206CrossRef
8.
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP, Raghavan D, Crawford ED: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New Engl J Med. 2003, 349 (9): 859-866. 10.1056/NEJMoa022148.CrossRefPubMed
9.
Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Nilsson S, Malmstrom PU: Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol. 2004, 45 (3): 297-303. 10.1016/j.eururo.2003.09.019.CrossRefPubMed
10.
Takahashi R, Kimata R, Nomura S, Matsuzawa I, Suzuki Y, Hamasaki T, Kondo Y: The role of serum cytokeratin 19 fragment in transarterial infusion against invasive bladder cancer. Open J Urol. 2013, 3 (3): 160-164. 10.4236/oju.2013.33030.CrossRef
11.
Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nature Rev Cancer. 2002, 2 (6): 442-454. 10.1038/nrc822.CrossRef
12.
Thiery JP, Chopin D: Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev. 1999, 18 (1): 31-42. 10.1023/A:1006256219004.CrossRefPubMed
13.
Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009, 138 (4): 645-659. 10.1016/j.cell.2009.06.034.CrossRefPubMedPubMedCentral
14.
Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006, 12 (14 Pt 1): 4147-4153.CrossRefPubMed
15.
Guaita S, Puig I, Franci C, Garrido M, Dominguez D, Batlle E, Sancho E, Dedhar S, De Herreros AG, Baulida J: Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem. 2002, 277 (42): 39209-39216. 10.1074/jbc.M206400200.CrossRefPubMed
16.
Boulay JL, Dennefeld C, Alberga A: The Drosophila developmental gene snail encodes a protein with nucleic acid binding fingers. Nature. 1987, 330 (6146): 395-398. 10.1038/330395a0.CrossRefPubMed
17.
Bruyere F, Namdarian B, Corcoran NM, Pedersen J, Ockrim J, Voelzke BB, Mete U, Costello AJ, Hovens CM: Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers. Urologic Oncol. 2010, 28 (6): 591-596. 10.1016/j.urolonc.2008.11.005.CrossRef
18.
Kosaka T, Kikuchi E, Mikami S, Miyajima A, Shirotake S, Ishida M, Okada Y, Oya M: Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion. Clin Cancer Res. 2010, 16 (23): 5814-5823. 10.1158/1078-0432.CCR-10-0230.CrossRefPubMed
19.
Hoshino H, Miyoshi N, Nagai K, Tomimaru Y, Nagano H, Sekimoto M, Doki Y, Mori M, Ishii H: Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer. Biochem Biophys Res Commun. 2009, 390 (3): 1061-1065. 10.1016/j.bbrc.2009.10.117.CrossRefPubMed
20.
Yin T, Wang C, Liu T, Zhao G, Zha Y, Yang M: Expression of snail in pancreatic cancer promotes metastasis and chemoresistance. J Surg Res. 2007, 141 (2): 196-203. 10.1016/j.jss.2006.09.027.CrossRefPubMed
21.
Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007, 18 (3): 522-528.CrossRefPubMed
22.
Font A, Taron M, Gago JL, Costa C, Sanchez JJ, Carrato C, Mora M, Celiz P, Perez L, Rodriguez D, Gimenez-Capitan A, Quiroga V, Benlloch S, Ibarz L, Rosell R: BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol. 2011, 22 (1): 139-144. 10.1093/annonc/mdq333.CrossRefPubMed
23.
Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stohr R, Stockle M, Lehmann J, Schuler M, Hartmann A: MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia. 2010, 12 (8): 628-636.CrossRefPubMedPubMedCentral
Metadata
Title
Snail expression and outcome in T1 high-grade and T2 bladder cancer: a retrospective immunohistochemical analysis
Authors
Shunichiro Nomura
Yasutomo Suzuki
Ryo Takahashi
Mika Terasaki
Ryoji Kimata
Tsutomu Hamasaki
Go Kimura
Akira Shimizu
Yukihiro Kondo
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2013
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-13-73

Other articles of this Issue 1/2013

BMC Urology 1/2013 Go to the issue

Research article

Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial

Research article

Elevated C-reactive protein values predict nodal metastasis in patients with penile cancer

Research article

The effect of indomethacin on the muscarinic induced contractions in the isolated normal guinea pig urinary bladder

Study protocol

A randomized controlled trial to assess the efficacy and cost-effectiveness of urinary catheters with silver alloy coating in spinal cord injured patients: trial protocol

Research article

Effect of combined psycho-physiological stretching and breathing therapy on sexual satisfaction

Research article

Identifying the quality of life effects of urinary incontinence with depression in an Australian population